Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation.
about
Danazol Treatment for Telomere DiseasesImmunosuppressive therapy for transplant-ineligible aplastic anemia patients.Bone marrow failure and the telomeropathies.Marrow failure: a window into ribosome biologyA novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibitionAccelerated telomere shortening in peripheral blood lymphocytes after occupational polychlorinated biphenyls exposure.Response to androgen therapy in patients with dyskeratosis congenita.Prognostic value of telomere attrition in patients with aplastic anemia.Pluripotent stem cells escape from senescence-associated DNA methylation changes.Oxandrolone for the treatment of bone marrow failure in Fanconi anemia.Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions.Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas.Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.
P2860
Q29307230-FB987445-6F1A-4D01-8584-AC1EE63BF502Q33419679-6EB76A61-C021-4A7A-A144-CB68622608FFQ34431411-0CF514A4-6199-443F-A7D4-E6F58A37D5F4Q34431422-3CA40514-840D-4B84-901F-84AEBCB19573Q36411101-84A7C218-B631-4ECA-8AA0-F934DEF27794Q37578307-1A5E108C-B3FC-45A5-A7DF-4FAC4971D42DQ37699500-09E0CCFD-BFE7-4629-82E0-00AC0747E32CQ38103469-00511FA0-20B0-4116-BF74-255D33145DC3Q39256627-4E740A6C-3F07-435E-833A-DC6E345C78E8Q46542103-576C5C27-DFA5-421F-98F6-050CBB5546B8Q47612537-D3785F17-B907-4177-970A-AB9992DEBD1DQ47913152-B20BB829-5F12-41CB-8BE6-16F1D4C937A1Q49803880-FEA83CB8-E264-44EA-9218-B7061BA91C18Q50561494-B1547637-00F8-433B-8A04-996D26088976Q55332823-1286FC50-6FEE-4580-BDC9-D743EC08BAAD
P2860
Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Telomere elongation and clinic ...... erozygous hTERT gene mutation.
@en
Telomere elongation and clinic ...... erozygous hTERT gene mutation.
@nl
type
label
Telomere elongation and clinic ...... erozygous hTERT gene mutation.
@en
Telomere elongation and clinic ...... erozygous hTERT gene mutation.
@nl
prefLabel
Telomere elongation and clinic ...... erozygous hTERT gene mutation.
@en
Telomere elongation and clinic ...... erozygous hTERT gene mutation.
@nl
P2093
P2860
P1433
P1476
Telomere elongation and clinic ...... erozygous hTERT gene mutation.
@en
P2093
Hubert Schrezenmeier
Jamil Akkad
Jens Panse
Klaus Schwarz
Lucia Vankann
Patrick Ziegler
Stefan Balabanov
Stefan Wilop
Tim H Brümmendorf
Ute Brassat
P2860
P304
P356
10.1007/S00277-012-1454-X
P577
2012-04-04T00:00:00Z